NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Hoth
Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a
biopharmaceutical company focused on developing new generation
therapies for dermatological disorders such as atopic dermatitis,
chronic wounds, psoriasis and acne, is pleased to announce the
initiation of a preclinical study for the treatment of asthma and
allergic inflammation in collaboration with North Carolina State University (NC State) beginning on January 1, 2020.
The goal of the study is to determine the best approach for
targeting allergic inflammation in the airways with
Splice-switching oligonucleotides (SSOs) and establish proof of
principle by providing preclinical mouse data to inform consequent
toxicology, ADME (absorption, distribution, metabolism and
excretion), and Pharmacokinetics (PK) study or how an organism
affects the drug.
The initial set of experiments look to establish the delivery of
SSOs targeting the gene encoding the FcεRIβ protein in the lungs of
mice by using an ultrasonic nebulizer and assessing its
distribution and function in mast cells throughout for a period of
one year by using RNA (Ribonucleic acid) scope technology. Once
effective delivery of SSOs to the lungs has been established and
determined that delivery of a target gene SSO reduces allergic
airway inflammation in a standard asthma mouse model, HOTH and
NC State plan to move on to the second
phase of the study.
During the second phase, the aim will be to determine the
efficacy of SSO combinations that target FcεRIβ and other genes
that function in the IgE receptor pathway, in airway inflammation
using humanized mouse models to establish which target gene(s) to
move forward with. The study will determine the efficacy, in vivo,
by administering SSOs for the target gene(s) and establishing
whether targeting FcεRIβ alone or in combination with other genes
provides the best therapeutic approach.
Mr. Robb Knie, Chief Executive
Officer of Hoth Therapeutics, Inc. commented, "After signing our
license agreement with NC State in
November 2019, we are pleased to
quickly move forward with the design of our preclinical study for
asthma. This study will not only allow us to identify and advance
drug candidates for asthma and other allergic diseases, but it will
also play a key role in reversing the progression of allergic
reactions in patients."
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc.
is a clinical-stage biopharmaceutical company focused on developing
new generation therapies for dermatological disorders. HOTH's
pipeline has the potential to improve the quality of life for
patients suffering from indications including atopic dermatitis,
chronic wounds, psoriasis, and acne. HOTH has the exclusive
worldwide rights to BioLexa, the company's proprietary lead drug
candidate topical platform that uniquely combines two FDA approved
compounds to fight bacterial infections across multiple
indications. HOTH is preparing to launch its clinical trial for the
treatment of adolescent subjects, 2-17 years of age, with mild to
moderate atopic dermatitis during 2020. To learn more, please
visit www.hoththerapeutics.com.
Forward Looking Statements
This press release includes
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release include, but are not limited to,
statements that relate to the advancement and development of the
BioLexa Platform, the commencement of clinical trials, the
availability of data from clinical trials and other information
that is not historical information. When used herein, words such as
"anticipate", "being", "will", "plan", "may", "continue", and
similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon
Hoth's current expectations and various assumptions. Hoth believes
there is a reasonable basis for its expectations and beliefs, but
they are inherently uncertain. Hoth may not realize its
expectations, and its beliefs may not prove correct. Actual results
could differ materially from those described or implied by such
forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption "Risk Factors" in Hoth's Form
10K for the period ending December 31,
2018, and Hoth's other filings made with the Securities and
Exchange Commission. Consequently, forward-looking statements
should be regarded solely as Hoth's current plans, estimates and
beliefs. Investors should not place undue reliance on
forward-looking statements. Hoth cannot guarantee future results,
events, levels of activity, performance or achievements. Hoth does
not undertake and specifically declines any obligation to update,
republish, or revise any forward-looking statements to reflect new
information, future events or circumstances or to reflect the
occurrences of unanticipated events, except as may be required by
law.
Contacts
Investor Relations Contact:
Phone: (646) 756-2997
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
KCSA Strategic Communications
Valter Pinto / Daniela Guerrero
(212) 896-1254 / (212) 682-6300
Hoth@kcsa.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-and-north-carolina-state-university-initiate-preclinical-gene-therapy-study-for-the-treatment-of-asthma-300971548.html
SOURCE Hoth Therapeutics, Inc.